Anaptysbio Inc (ANAB)

$19.18

-0.48

(-2.44%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Anaptysbio Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 3.31M → 9.00M (in $), with an average increase of 63.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -37.30M → -42.21M (in $), with an average decrease of 13.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.9% return, outperforming this stock by 62.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 266.2%

Performance

  • $19.17
    $20.45
    $19.18
    downward going graph

    0.05%

    Downside

    Day's Volatility :6.26%

    Upside

    6.21%

    downward going graph
  • $13.36
    $27.50
    $19.18
    downward going graph

    30.34%

    Downside

    52 Weeks Volatility :51.42%

    Upside

    30.25%

    downward going graph

Returns

PeriodAnaptysbio IncSector (Health Care)Index (Russel 2000)
3 Months
-19.0%
1.9%
0.0%
6 Months
8.67%
10.7%
0.0%
1 Year
-11.45%
4.6%
-1.1%
3 Years
-20.38%
14.2%
-22.1%

Highlights

Market Capitalization
526.2M
Book Value
$3.31
Earnings Per Share (EPS)
-6.08
PEG Ratio
0.0
Wall Street Target Price
45.22
Profit Margin
0.0%
Operating Margin TTM
-386.41%
Return On Assets TTM
-18.47%
Return On Equity TTM
-93.44%
Revenue TTM
17.2M
Revenue Per Share TTM
0.64
Quarterly Revenue Growth YOY
32.300000000000004%
Gross Profit TTM
-78.5M
EBITDA
-156.4M
Diluted Eps TTM
-6.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-6.21
EPS Estimate Next Year
-5.96
EPS Estimate Current Quarter
-1.6
EPS Estimate Next Quarter
-1.59

Analyst Recommendation

Buy
    58%Buy
    41%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Anaptysbio Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 135.77%

Current $19.18
Target $45.22

Company Financials

FY18Y/Y Change
Revenue
5.0M
↓ 50.0%
Net Income
-61.7M
↑ 105.04%
Net Profit Margin
-1.2K%
↓ 932.42%
FY19Y/Y Change
Revenue
8.0M
↑ 60.0%
Net Income
-97.3M
↑ 57.87%
Net Profit Margin
-1.2K%
↑ 16.42%
FY20Y/Y Change
Revenue
75.0M
↑ 837.5%
Net Income
-19.9M
↓ 79.53%
Net Profit Margin
-26.56%
↑ 1190.14%
FY21Y/Y Change
Revenue
63.2M
↓ 15.77%
Net Income
-57.2M
↑ 187.11%
Net Profit Margin
-90.53%
↓ 63.97%
FY22Y/Y Change
Revenue
10.3M
↓ 83.72%
Net Income
-128.7M
↑ 125.07%
Net Profit Margin
-1.3K%
↓ 1160.8%
FY23Y/Y Change
Revenue
17.2M
↑ 66.78%
Net Income
-163.6M
↑ 27.11%
Net Profit Margin
-953.66%
↑ 297.67%
Q3 FY22Q/Q Change
Revenue
1.3M
↑ 6.33%
Net Income
-37.4M
↑ 0.17%
Net Profit Margin
-2.9K%
↑ 177.91%
Q4 FY22Q/Q Change
Revenue
6.8M
↑ 426.53%
Net Income
-26.4M
↓ 29.32%
Net Profit Margin
-387.97%
↑ 2502.29%
Q1 FY23Q/Q Change
Revenue
1.4M
↓ 79.82%
Net Income
-48.4M
↑ 83.41%
Net Profit Margin
-3.5K%
↓ 3137.87%
Q2 FY23Q/Q Change
Revenue
3.5M
↑ 151.82%
Net Income
-39.8M
↓ 17.75%
Net Profit Margin
-1.2K%
↑ 2374.25%
Q3 FY23Q/Q Change
Revenue
3.3M
↓ 4.1%
Net Income
-37.3M
↓ 6.37%
Net Profit Margin
-1.1K%
↑ 27.18%
Q4 FY23Q/Q Change
Revenue
9.0M
↑ 171.4%
Net Income
-42.2M
↑ 13.14%
Net Profit Margin
-468.75%
↑ 655.66%
FY18Y/Y Change
Total Assets
509.0M
↑ 54.54%
Total Liabilities
22.6M
↑ 3.9%
FY19Y/Y Change
Total Assets
435.2M
↓ 14.5%
Total Liabilities
30.2M
↑ 33.39%
FY20Y/Y Change
Total Assets
416.6M
↓ 4.28%
Total Liabilities
19.8M
↓ 34.34%
FY21Y/Y Change
Total Assets
643.1M
↑ 54.38%
Total Liabilities
286.6M
↑ 1346.15%
FY22Y/Y Change
Total Assets
610.4M
↓ 5.08%
Total Liabilities
348.3M
↑ 21.5%
FY23Y/Y Change
Total Assets
452.4M
↓ 25.88%
Total Liabilities
364.3M
↑ 4.6%
Q3 FY22Q/Q Change
Total Assets
618.5M
↑ 2.43%
Total Liabilities
340.9M
↑ 13.8%
Q4 FY22Q/Q Change
Total Assets
610.4M
↓ 1.31%
Total Liabilities
348.3M
↑ 2.17%
Q1 FY23Q/Q Change
Total Assets
551.8M
↓ 9.6%
Total Liabilities
360.7M
↑ 3.57%
Q2 FY23Q/Q Change
Total Assets
517.1M
↓ 6.29%
Total Liabilities
368.7M
↑ 2.2%
Q3 FY23Q/Q Change
Total Assets
487.3M
↓ 5.76%
Total Liabilities
366.9M
↓ 0.46%
Q4 FY23Q/Q Change
Total Assets
452.4M
↓ 7.17%
Total Liabilities
364.3M
↓ 0.72%
FY18Y/Y Change
Operating Cash Flow
-48.5M
↑ 149.54%
Investing Cash Flow
-142.5M
↓ 41.39%
Financing Cash Flow
223.4M
↓ 23.62%
FY19Y/Y Change
Operating Cash Flow
-69.5M
↑ 43.32%
Investing Cash Flow
131.4M
↓ 192.26%
Financing Cash Flow
-4.5M
↓ 102.01%
FY20Y/Y Change
Operating Cash Flow
-14.2M
↓ 79.64%
Investing Cash Flow
94.5M
↓ 28.12%
Financing Cash Flow
-879.0K
↓ 80.44%
FY21Y/Y Change
Operating Cash Flow
-45.9M
↑ 224.36%
Investing Cash Flow
38.8M
↓ 58.89%
Financing Cash Flow
252.3M
↓ 28802.84%
FY22Y/Y Change
Operating Cash Flow
-73.6M
↑ 60.26%
Investing Cash Flow
-394.8M
↓ 1116.72%
Financing Cash Flow
44.0M
↓ 82.55%
Q3 FY22Q/Q Change
Operating Cash Flow
-17.7M
↓ 26.5%
Investing Cash Flow
-32.4M
↓ 54.32%
Financing Cash Flow
37.0M
↑ 8471.06%
Q4 FY22Q/Q Change
Operating Cash Flow
-10.7M
↓ 39.79%
Investing Cash Flow
21.5M
↓ 166.28%
Financing Cash Flow
1.9M
↓ 94.74%
Q1 FY23Q/Q Change
Operating Cash Flow
-24.6M
↑ 129.93%
Investing Cash Flow
85.4M
↑ 297.25%
Financing Cash Flow
-37.6M
↓ 2027.86%
Q2 FY23Q/Q Change
Operating Cash Flow
-25.4M
↑ 3.42%
Investing Cash Flow
-20.5M
↓ 123.95%
Financing Cash Flow
-13.5M
↓ 64.09%
Q3 FY23Q/Q Change
Operating Cash Flow
-36.5M
↑ 43.55%
Investing Cash Flow
30.6M
↓ 249.77%
Financing Cash Flow
-3.1M
↓ 77.23%

Technicals Summary

Sell

Neutral

Buy

Anaptysbio Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Anaptysbio Inc
Anaptysbio Inc
-9.1%
8.67%
-11.45%
-20.38%
-73.82%
Moderna, Inc.
Moderna, Inc.
-2.26%
35.27%
-21.9%
-39.25%
318.83%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.59%
12.81%
13.84%
81.04%
166.5%
Novo Nordisk A/s
Novo Nordisk A/s
-0.32%
31.91%
50.92%
247.21%
431.9%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.67%
9.62%
21.65%
86.62%
134.62%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Anaptysbio Inc
Anaptysbio Inc
NA
NA
0.0
-6.21
-0.93
-0.18
NA
3.31
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.9
25.9
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.09
47.09
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.76
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Anaptysbio Inc
Anaptysbio Inc
Buy
$526.2M
-73.82%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.0B
318.83%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.8B
166.5%
25.9
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$558.9B
431.9%
47.09
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.4B
134.62%
28.81
36.68%

Institutional Holdings

  • EcoR1 Capital, LLC

    28.30%

  • Deep Track Capital, LP

    7.67%

  • TANG CAPITAL MANAGEMENT LLC

    7.34%

  • BlackRock Inc

    6.86%

  • Vanguard Group Inc

    6.41%

  • Boxer Capital LLC

    4.89%

Corporate Announcements

  • Anaptysbio Inc Earnings

    Anaptysbio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c

Organization
Anaptysbio Inc
Employees
117
CEO
Mr. Daniel R. Faga
Industry
Health Technology

Discover More

FAQs